Rhythm Pharmaceuticals (RYTM) Change in Account Payables (2016 - 2017)
Rhythm Pharmaceuticals' (RYTM) quarterly Change in Account Payables came in at -$105000.0 in Q1 2017, up 82.76% on a QoQ basis from -$609000.0 in Q4 2016.
Rhythm Pharmaceuticals (RYTM) Change in Account Payables (2016 - 2017) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 2 years of Change in Account Payables data on file, last reported at -$105000.0 in Q1 2017.
- On a quarterly basis, Change in Account Payables changed N/A year-over-year to -$105000.0 in Q1 2017; TTM through Dec 2017 was -$105000.0, a N/A change from a year earlier, with the FY2017 full-year figure at -$105000.0, up 77.66% from the prior year.
- Change in Account Payables for Q1 2017 stood at -$105000.0, up from -$609000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for RYTM reached as high as -$105000.0 in Q1 2017 and fell as low as -$609000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 16.86 Mn |
| 10 | Rhythm Pharmaceuticals | 6.99 Bn | 6.64 Bn | 52.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -105,000.00 |
| Mar 31, 2017 | -105,000.00 |
| Dec 31, 2016 | -609,000.00 |
| Dec 31, 2016 | -609,000.00 |